Rocket Pharmaceuticals, Inc. (RCKT)

NASDAQ: RCKT · IEX Real-Time Price · USD

22.82

-0.22 (-0.95%)

At close: Jul 19, 2024, 4:00 PM

22.87

+0.05 (0.22%)

Pre-market: Jul 20, 2024, 9:29 AM EDT

Rocket Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2012
Selling, General & Admin	79.64	73.32	58.77	41.77	28.87	18.24	Upgrade
Research & Development	185.2	186.34	165.57	125.48	105.44	57.91	Upgrade
Operating Expenses	264.84	259.66	224.34	167.25	134.3	76.15	Upgrade
Operating Income	-264.84	-259.66	-224.34	-167.25	-134.3	-76.15	Upgrade
Interest Expense / Income	1.88	1.88	1.86	2.98	6.97	5.96	Upgrade
Other Expense / Income	-17.4	-15.94	-4.34	-1.16	-1.57	-4.84	Upgrade
Pretax Income	-249.31	-245.6	-221.86	-169.07	-139.7	-77.27	Upgrade
Net Income	-249.31	-245.6	-221.86	-169.07	-139.7	-77.27	Upgrade
Shares Outstanding (Basic)	94	84	68	63	55	49	Upgrade
Shares Outstanding (Diluted)	94	84	68	63	55	49	Upgrade
Shares Change	17.74%	23.27%	7.77%	14.18%	13.00%	24.46%	Upgrade
EPS (Basic)	-2.85	-2.92	-3.26	-2.67	-2.52	-1.58	Upgrade
EPS (Diluted)	-2.85	-2.92	-3.26	-2.67	-2.52	-1.58	Upgrade
Free Cash Flow	-209.7	-211.39	-186.76	-128.88	-103.7	-87.93	Upgrade
Free Cash Flow Per Share	-2.24	-2.52	-2.74	-2.04	-1.87	-1.79	Upgrade
EBITDA	-239.76	-236.62	-213.74	-160.72	-126.48	-70.89	Upgrade
Depreciation & Amortization	7.68	7.1	6.27	5.37	6.25	0.43	Upgrade
EBIT	-247.44	-243.72	-220	-166.09	-132.73	-71.31	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).